A Cannabinoid 2-Selective Agonist Inhibits Allogeneic Skin Graft Rejection In Vivo
Previous work from our laboratory showed that a CB2 selective agonist, O-1966, blocked the proliferative response of C57BL/6 mouse spleen cells exposed to spleen cells of C3HeB/FeJ mice in vitro in the mixed lymphocyte reaction (MLR). The MLR is widely accepted as an in vitro correlate of in vivo gr...
Saved in:
Main Authors: | Senthil Jayarajan (Author), Joseph J. Meissler (Author), Martin W. Adler (Author), Toby K. Eisenstein (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival
by: Aaron Prodeus, et al.
Published: (2014) -
Mesenchymal stem cells avoid allogeneic rejection
by: Murphy J Mary, et al.
Published: (2005) -
Cannabinoid Receptor Agonist Inhibits Atrial Electrical Remodeling in a Tachypaced Ex Vivo Rat Model
by: Danielle I. Lee, et al.
Published: (2021) -
Rituximab monotherapy in precursor-B-Cell acute Lymphoblastic leukaemia: Managing relapse or graft rejection post-allogenic bone marrow transplant
by: Rachit Khandelwal, et al.
Published: (2024) -
Understanding the Perceived Threat of the Risk of Graft Rejections
by: Anna Forsberg, et al.
Published: (2015)